Allogene Reports Updated Results from ALLO-316 in Renal Carcinoma; AACR 2023 Analysis 2
AACR 2023 Analysis 2: Allogene reported updated clinical data from its Ph1 TRAVERSE trial evaluating ALLO-316 (allogeneic CD70 CAR-T) in clear cell renal carcinoma (ccRCC). Below, Celltelligence provides insights on the clinical data from ALLO-316 in ccRCC while discussing potential strategies that Allogene could develop to improve ALLO-316 potency in solid tumors.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.